» Articles » PMID: 36741702

Mapping the Tumor Microenvironment in Bladder Cancer and Exploring the Prognostic Genes by Single-cell RNA Sequencing

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Feb 6
PMID 36741702
Authors
Affiliations
Soon will be listed here.
Abstract

Despite substantial advances in the treatment using immune checkpoint inhibitors (ICIs), the clinical expected therapeutic effect on bladder cancer has not been achieved, in which the tumor microenvironment (TME) occupies a notable position. In this research, 10X single-cell RNA-sequencing technology was conducted to analyze seven primary bladder tumor tissues (three non-muscle-invasive bladder cancer (NMIBC) and four muscle-invasive bladder cancer (MIBC)) and seven corresponding normal tissues adjacent to cancer; eight various cell types were identified in the bladder cancer (BC) TME, and a complete TME atlas in bladder cancer was made. Moreover, bladder cancer epithelial cells were further subdivided into 14 subgroups, indicating a high intra-tumoral heterogeneity. Additionally, the differences between NMIBC and MIBC were compared based on differential gene expression heatmap, copy number variation (CNV) distribution heatmap, Gene Ontology (GO) enrichment analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) network mutual analysis, and the Kaplan-Meier survival prognosis analysis were used to identify six key genes associated with the prognosis of bladder cancer: VEGFA, ANXA1, HSP90B1, PSMA7, PRDX6, and PPP1CB. The dynamic change of the expression distribution of six genes on the pseudo-time axis was further verified by cell pseudo-time analysis.

Citing Articles

Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells.

Johnson 3rd B, Parimi V, Kamanda S, Corney D, Choi W, Hoffman-Censits J J Pathol Clin Res. 2025; 11(2):e70021.

PMID: 39971624 PMC: 11839278. DOI: 10.1002/2056-4538.70021.


A Pilot Study of Exosome Proteomic Profiling Reveals Dysregulated Metabolic Pathways in Endometrial Cancer.

Kharrat F, Capaci V, Conti A, Golino V, Campiglia P, Balasan N Biomedicines. 2025; 13(1).

PMID: 39857679 PMC: 11759861. DOI: 10.3390/biomedicines13010095.


Recent contributions of single-cell and spatial profiling to the understanding of bladder cancer.

Grausenburger R, Herek P, Shariat S, Englinger B Curr Opin Urol. 2024; 34(4):236-243.

PMID: 38650456 PMC: 11155276. DOI: 10.1097/MOU.0000000000001183.

References
1.
Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y . Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020; 11(1):5077. PMC: 7545162. DOI: 10.1038/s41467-020-18916-5. View

2.
Shariat S . Editorial comment on: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. Eur Urol. 2008; 56(4):688-9. DOI: 10.1016/j.eururo.2008.05.028. View

3.
Omorphos N, Piedad J, Vasdev N . Guideline of guidelines: Muscle-invasive bladder cancer. Turk J Urol. 2020; 47(Supp. 1):S71-S78. PMC: 8057355. DOI: 10.5152/tud.2020.20337. View

4.
Wu W, Jia G, Chen L, Liu H, Xia S . Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer. Front Genet. 2021; 12:731625. PMC: 8414640. DOI: 10.3389/fgene.2021.731625. View

5.
Liang Z, Li X . Identification of ANXA1 as a potential prognostic biomarker and correlating with immune infiltrates in colorectal cancer. Autoimmunity. 2021; 54(2):76-87. DOI: 10.1080/08916934.2021.1887148. View